Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 13/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 13/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018740 | 0.87 | GRIN1 (1.00) | GRIN1GRIN2BKCNH2ALDH1A1SLC6A2 | |
| SCHEMBL12575509 | 0.86 | GRIN1 (0.76) | GRIN1GRIN2BALDH1A1KDM4ELMNA | |
| SCHEMBL2022989 | 0.86 | GRIN1 (0.76) | GRIN1GRIN2BKCNH2SLC6A2SLC6A3 | |
| SCHEMBL2022077 | 0.85 | GRIN1 (1.00) | GRIN1GRIN2BKCNH2ALDH1A1SLC6A2 | |
| SCHEMBL8018391 | 0.85 | GRIN1 (1.00) | GRIN1GRIN2BKCNH2ALDH1A1SLC6A2 | |
| SCHEMBL12640606 | 0.85 | GRIN1 (0.82) | GRIN1GRIN2BKCNH2ALDH1A1KDM4E | |
| SCHEMBL2020842 | 0.84 | GRIN1 (1.00) | GRIN1GRIN2BKCNH2SLC6A2SLC6A3 | |
| SCHEMBL2019889 | 0.82 | GRIN1 (0.69) | GRIN1GRIN2BALDH1A1KDM4ELMNA | |
| SCHEMBL2019494 | 0.82 | GRIN1 (0.69) | GRIN1GRIN2BALDH1A1KDM4ELMNA | |
| SCHEMBL13656132 | 0.81 | GRIN1 (0.67) | GRIN1GRIN2BALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| WO-2009137843-A2 | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EMORY UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
| WO-2009006437-A1 | NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION | EMORY UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | GRIN1 1/4885GRIN2B 7/4885KCNH2 137/4885 |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | GRIN1 3/4885GRIN2B 2/4885KCNH2 469/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | GRIN1 1/4885GRIN2B 7/4885KCNH2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.